Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01569451 · ClinicalTrials.gov registry record · Phase 2
Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate
A Phase 2 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
NCT01569451 is a Phase 2 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 53 participants.
The verdict
NCT01569451, a Phase 2 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
Study Summary
The purpose of this study is (1) to determine if rituximab induction therapy followed by glatiramer acetate (GA) is substantially superior to placebo rituximab induction followed by GA for the treatment of clinically isolated syndrome (CIS) or relapsing forms of multiple sclerosis (RMS).
Interventions
- OTHER Placebo
- DRUG Rituximab
- DRUG Glatiramer Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01569451
The ClinicalTrials.gov registry entry for NCT01569451 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01569451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01569451 about?
NCT01569451 is a clinical study titled "Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate". The purpose of this study is (1) to determine if rituximab induction therapy followed by glatiramer acetate (GA) is substantially superior to placebo rituximab induction followed by GA for the treatment of clinically isolated syndrome (CIS) or relapsing forms of multiple sclerosis (RMS).
What is the current status of trial NCT01569451?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2012-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01569451?
The interventions under investigation include: Placebo (OTHER), Rituximab (DRUG), Glatiramer Acetate (DRUG).
Who is sponsoring clinical trial NCT01569451?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.